32

Tubulin inhibitor 32 is an orally active novel microtubule inhibitor with antiproliferative and antitumor activity, inhibits microtubule polymerization, induces apoptosis and cell cycle arrest in G2/M phase.

hMAO-B-IN-32 is a potent hMAO-B selective inhibitor with an IC50 of 45.52 μM.

GLP-1(32-36)amide acetate is a pentapeptide and derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide acetate could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.

Peptide T acetate is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action

(3R,4R)-A2-32-01 is the (R,R)-enantiomer of A2-32-01 and has potential antibacterial activity.

DiZPK Hydrochloride is a structural analog of pyrrolysine (Pyl), acting as a photocrosslinker for identifying direct protein-protein interactions in living prokaryotic and eukaryotic cells.

KU-32 is a novel and novobiocin-based Hsp90 inhibitor. It can protect against neuronal cell death.

HSP90-IN-32, a carboxy-terminus inhibitor of Hsp90C, exhibits antiproliferative activity in various cell lines including SKMel173, SKMel103, SKMel19, and A375, with IC50 values of 1.01 μM, 0.782 μM, 0.607 μM, and 1.413 μM, respectively. This compound holds potential for research in anticancer agents.

SHP2-IN-32 (compound C6) is an orally effective allosteric SHP2 inhibitor with an IC50 value of 0.13 nM. It demonstrates antitumor activity.

PROTAC SMARCA2 4-degrader-32 (compound I-446) is a PROTAC degrader targeting both SMARCA2 and SMARCA4 proteins. In A549 cells, it shows DC50s values for the degradation of SMARCA2 4 proteins <100 nM and achieves a maximum degradation rate (Dmax%) of >90 after 24 hours of treatment.

PCSK9-IN-32 (compound 8) acts as an inhibitor of PCSK9[1:33]-GFP translation.

KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.

RORγt inverse agonist 32 (compound b14) exhibits oral activity and can be utilized in inflammatory research studies.

PARP-1-IN-32 (compound 15) is an inhibitor of poly (ADPribose) polymerase-1 (PARP-1), specifically designed for use in cancer research.

CDK2-IN-32 (Compound 5g) is a selective CDK2 inhibitor with an IC50 of 0.21 μM. It exhibits cytotoxicity towards Vero cells with an IC50 of 28.52 μM.

SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective inhibitor of SARS-CoV-2 MPro with an IC50 value of 230 nM. In vitro, it also inhibits the replication of various SARS-CoV-2 variants.

ENPP1 inhibitor 32 is an ENPP1 inhibitor with antitumor activity.

PROTAC SMARCA2 degrader-32 (Compound 27) is an effective degrader of SMARCA2, with a DC50 of 1.3 nM. It inhibits the proliferation of lung cancer cells NCI-H838 with a GI50 of 34 nM.

Apoptosisinducer 32 (Compound 7g) is an apoptosis inducer with a KD of 42 μM, demonstrating antitumor activity by causing significant morphological changes, such as membrane blebbing, nuclear fragmentation, and apoptotic body formation, in MDA-MB-231 cells. The IC50 values for Apoptosisinducer 32 are 4.77 μM in MCF-7 cells, 6.56 μM in MDA-MB-231 cells, and 337.8 μM in HEK cells.

AR ligand-32 is a ligand for target proteins, employed in the synthesis of PROTAC AR Degrader-7.

CDK7-IN-32 (compound10) is an inhibitor of CDK7.

KUM 32 is a potent antagonist of adrenaline-induced platelet aggregation. It acts as an inhibitor of adenylate cyclase activity and binds to the alpha 2-adrenergic receptor on human platelets.

KI-CDK9d-32 is a CDK9 PROTAC degrader with a DC50 of 0.89 nM. It facilitates the ubiquitination and degradation of CDK9, inhibits the MYC pathway, and disrupts nucleolar homeostasis. KI-CDK9d-32 demonstrates anticancer activity.

PROTACBRD4 Degrader-32 (Compound 22) is a potent BRD4 PROTAC degrader with a DC50 of 0.20 nM. It employs a unique carbon-carbon linker to connect the BRD4 binding domain with the CRBN binding domain, forming a ternary complex that induces BRD4 ubiquitination and facilitates proteasomal degradation. PROTACBRD4 Degrader-32 holds promise for research into BRD4-related cancers, such as hematological malignancies.